Neurocrine Biosciences Inc (NBIX)
Total asset turnover
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 2,355,100 | 1,883,200 | 1,411,600 | 1,107,700 | 994,700 |
| Total assets | US$ in thousands | 3,718,700 | 3,251,400 | 2,368,700 | 2,072,500 | 1,734,700 |
| Total asset turnover | 0.63 | 0.58 | 0.60 | 0.53 | 0.57 |
December 31, 2024 calculation
Total asset turnover = Revenue ÷ Total assets
= $2,355,100K ÷ $3,718,700K
= 0.63
Neurocrine Biosciences Inc has displayed fluctuations in its total asset turnover ratio over the years, as indicated by the values provided. The total asset turnover ratio measures a company's efficiency in utilizing its assets to generate revenue. A higher ratio generally implies better asset utilization.
In 2020, the company's total asset turnover ratio was 0.57, indicating that for every dollar of assets held, Neurocrine Biosciences generated $0.57 in revenue. However, by the end of 2021, the ratio decreased to 0.53, suggesting a potential decline in asset efficiency.
Subsequently, in 2022, the total asset turnover ratio improved to 0.60, reflecting a more effective utilization of assets to generate revenue. The following year, in 2023, the ratio dipped slightly to 0.58, signaling a slight reduction in asset efficiency.
The most recent data point, at the end of 2024, shows a total asset turnover ratio of 0.63, indicating a positive trend towards improved asset utilization efficiency. Overall, Neurocrine Biosciences Inc has experienced varying levels of asset turnover efficiency over the years, with fluctuations that may warrant further investigation to understand the underlying factors driving these changes.
Peer comparison
Dec 31, 2024